Immunotherapies directed at programmed death ligand 1 (PD-L1) and its receptor (PD-1) have enhanced the survival rate of a group of patients with advanced lung cancer. Extensive research is being conducted to investigate better patient stratification.
Our PD-L1 solution is fully automated and does not require manual input during analysis. The solution consists of four automated analysis steps. Once started, it automatically separates the sample tissue from control tissues and robustly identifies invasive cancer areas in the sample. Tumor cells are counted based on their PD-L1 expression and the resulting Tumor Proportion Score (TPS) for the whole tumor area is calculated.